Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 33 clinical trials
Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE) (BladderGATE)

-specific CD8 T-cells, impairing cytokine production and diminishing the toxicity of activated T-cells. PD-L1 expression by immunohistochemistry using the Ventana SP142 assay on tumor-infiltrating immune

bladder cancer
carcinoma in situ
transurethral resection
expression by immunohistochemistry
bacillus calmette-guerin
  • 1 views
  • 21 Mar, 2022
Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer

Background: Locally advanced head and neck cancer (HNC) is a challenge as, in spite of initial good control with chemoradiation, the majority of patients fails systemically. In the last 2 years, immune check points inhibitors (mainly Programmed Death (PD)-1 inhibitors) were approved for metastatic/recurrent HNC. The favorable toxicity profile and …

  • 55 views
  • 15 Feb, 2022
  • 1 location
Adoptive Transfer of MUC1 Activated T Cells for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma

This phase I trial tests the safety, side effects and best dose of MUC1-activated T cells in treating patients with multiple myeloma that has come back (relapsed) or does not respond to

  • 0 views
  • 14 Jul, 2022
  • 1 location
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (SAGAN)

Subjects on this study have a type of lymph gland cancer called Non-Hodgkin Lymphoma, acute lymphocytic leukemia, or chronic Lymphocytic Leukemia (these diseases will be referred to as "lymphoma" or "leukemia"). The lymphoma or leukemia has come back or has not gone away after treatment. The body has different ways …

b-cell lymphoma
cancer
lymphoma
oximetry
cell transplantation
  • 69 views
  • 21 Mar, 2022
  • 2 locations
[18F]F-AraG PET Imaging to Visualize Tumor Infiltrating T-cell Activation in Non-small Cell Lung Cancer. (ATTAIN)

[18F]F-AraG is a promising tracer to image activated T-cells with positron emission tomography (PET). The aim of the ATTAIN trial is to investigate the pharmacokinetic characteristics of this

lung carcinoma
  • 0 views
  • 24 Mar, 2022
  • 1 location
A Phase 1b Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients

binds to human CTLA-4. ADG106, a fully human ligand-blocking agonistic anti-CD137 IgG4 mAb, is expected to enhance the activity of activated T cells. The enhanced antitumor efficacy results observed

  • 1 views
  • 22 Mar, 2022
  • 4 locations
BATs Treatment for Pancreatic Cancer, Phase Ib/II

This protocol will confirm toxicities and estimate the clinical efficacy of combining anti-CD3 x anti-EGFR bispecific antibody (EGFRBi) armed activated T cells (EGFR BATs) given to patients with

neutrophil count
cancer
serum total bilirubin
metastatic pancreatic cancer
biliary stenting
  • 42 views
  • 19 Apr, 2022
  • 1 location
BATs in Patients With Breast Cancer and Leptomeningeal Metastases

This study uses bi-specific antibody (HER2Bi) armed activated T-cells (HER2 BATs) to target breast cancer cells that have metastasized to the membranes surrounding the brain and spinal cord

HER2
breast cancer
cancer
neutrophil count
estrogen receptor
  • 3 views
  • 03 Feb, 2022
  • 1 location
Her2-BATS and Pembrolizumab in Metastatic Breast Cancer (Breast-47)

This proposal uses HER2Bi armed activated T-cells (HER2 BATs) to target breast cancer in combination with pembrolizumab (PBZ) in women with metastatic breast cancer (MBC). Phase I will determine

measurable disease
aptt
ct scan
estrogen
HER2
  • 8 views
  • 31 Jan, 2022
  • 1 location
Inducing Immune Quiescence the Genital Tract With ASA (IIQ-2)

activated T cells, increased levels of systemic T regulatory, increased production of anti-viral anti-protease serpins at the female genital tract and reduced numbers of HIV target cells (mainly CD4+ CCR5

HIV Vaccine
protease
Accepts healthy volunteers
AIDS
  • 0 views
  • 22 Mar, 2022
  • 1 location